LISBON, October 19 (Xinhua) – On Tuesday (October 18) the Portuguese start-up Immunethep. The Paragon Novell (PNV) vaccine, the world’s first multibacterial vaccine, has been released. It will receive 2.5 million euros (approximately 93.7 million baht) in funding to advance human clinical trials.
These tests will evaluate safety. immune stimulation and the initial efficacy of the Paragon Novel vaccine, which could receive 17.5 million euros (approximately 656 million baht) in global long-term investment.
Previous reports have indicated that the Novell Paragon vaccine protects against five bacterial infections, including pneumococcus. (pneumococcus), which is the cause of pneumonia and called the product a revolution in vaccines.
Bruno Santos, co-founder and executive director of Immuntep He said the Paragon Novel vaccine will fight antibiotic-resistant bacteria linked to hospital-acquired infections. This creates serious global problems and the company has been negotiating clinical trials with investors.
